Compare Medpace Holdings Inc (MEDP) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs TORM plc — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while TORM plc trades at $39.94 (market cap $4.12B). The key difference: Medpace Holdings Inc is far larger — about 4.1× TORM plc's market cap, and TORM plc pays a 11.03% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and TORM plc for 23 Days on average.
| MEDP | TRMD | |
|---|---|---|
Market Cap | $16.82B | $4.12B |
Volume | 223,093 | 2,863,116 |
Sector | Health | Industrials |
52-Week High | $630.19 | $41.05 |
52-Week Low | $393.42 | $19.39 |
Typical Hold Time | 14 Days | 23 Days |
Enterprise Value | $16.44B | $4.83B |
Dividend Yield | — | 11.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down slightly by 0.26% on the day, with a neutral technical outlook and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue and net income are projected to grow in 2026, supported by a robust 17.67% net income margin and exceptional ROE of 162.15%. However, valuation ratios like P/E of 35.41 and P/B of 38.77 suggest a premium pricing relative to peers.
The stock offers upside to the consensus price target of $620.44, but risks include high valuation multiples, CEO stock sales, and mixed institutional positioning. Investors should weigh strong profitability against potential overvaluation and monitor Q3 earnings for continued momentum.
TRMD trades at $40.06, up 2.93% today, with a bullish technical signal from moving averages. The stock shows strong profitability with a 35.52% net income margin and attractive valuation ratios, including a P/E of 6.59. Recent earnings saw a beat in Q4 2025 but misses in Q1 and Q2 2026, while Q3 2026 results are pending. A $2.40 dividend is scheduled for September 2026, and cash flow trends improved to a net positive in 2026. Analyst consensus is unanimously bullish with 100% buy ratings.
The outlook for TRMD is positive due to robust fundamentals and strong analyst support, but near-term risks include volatile spot rates impacting revenue and insider selling. The stock's valuation remains compelling, though dependence on freight rate sustainability poses a headwind. Investors should weigh the high dividend yield against cyclical industry exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
